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ABSTRACT Intrahost genetic diversity and replication error rates are intricately
linked to RNA virus pathogenesis, with alterations in viral polymerase ﬁdelity typi-
cally leading to attenuation during infections in vivo. We have previously shown that
norovirus intrahost genetic diversity also inﬂuences viral pathogenesis using the mu-
rine norovirus model, as increasing viral mutation frequency using a mutagenic nu-
cleoside resulted in clearance of a persistent infection in mice. Given the role of rep-
lication ﬁdelity and genetic diversity in pathogenesis, we have now investigated
whether polymerase ﬁdelity can also impact virus transmission between susceptible
hosts. We have identiﬁed a high-ﬁdelity norovirus RNA-dependent RNA polymerase
mutant (I391L) which displays delayed replication kinetics in vivo but not in cell cul-
ture. The I391L polymerase mutant also exhibited lower transmission rates between
susceptible hosts than the wild-type virus and, most notably, another replication de-
fective mutant that has wild-type levels of polymerase ﬁdelity. These results provide
the ﬁrst experimental evidence that norovirus polymerase ﬁdelity contributes to vi-
rus transmission between hosts and that maintaining diversity is important for the
establishment of infection. This work supports the hypothesis that the reduced poly-
merase ﬁdelity of the pandemic GII.4 human norovirus isolates may contribute to
their global dominance.
IMPORTANCE Virus replication ﬁdelity and hence the intrahost genetic diversity of
viral populations are known to be intricately linked to viral pathogenesis and tro-
pism as well as to immune and antiviral escape during infection. In this study, we
investigated whether changes in replication ﬁdelity can impact the ability of a virus
to transmit between susceptible hosts by the use of a mouse model for norovirus.
We show that a variant encoding a high-ﬁdelity polymerase is transmitted less efﬁ-
ciently between mice than the wild-type strain. This constitutes the ﬁrst experimen-
tal demonstration that the polymerase ﬁdelity of viruses can impact transmission of
infection in their natural hosts. These results provide further insight into potential
reasons for the global emergence of pandemic human noroviruses that display alter-
ations in the replication ﬁdelity of their polymerases compared to nonpandemic
strains.
KEYWORDS: RNA polymerases, noroviruses, polymerase ﬁdelity, quasispecies, virus
transmission
Replication ﬁdelity is a major trait inﬂuencing the pathogenesis of RNA viruses. Thehigh error rates of viral RNA polymerases during genome replication result in
genetically diverse virus populations, known as quasispecies, which are extremely
ﬂexible and adaptable to dynamic host environments and selection pressures (re-
viewed in reference 1). Alterations in replication ﬁdelity typically lead to reduced virus
infectivity in the host (2–5). This evidence has led to studies on the development of
antiviral strategies based on the manipulation of virus replication ﬁdelity. Such strate-
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gies have involved either the use of mutagenic compounds that can drive viral
extinction through increased replication error rates (lethal mutagenesis; reviewed in
references 6 and 7) or the design of mutant viruses with altered ﬁdelity causing an
attenuated phenotype in vivo, which can be used for the development of live vaccine
candidates (4, 8, 9).
We recently demonstrated the antiviral activity of a novel mutagenic nucleoside,
namely, T-705, or favipiravir, against persistent norovirus infections in vivo (10), pro-
viding the ﬁrst link between norovirus polymerase ﬁdelity and norovirus pathogenesis.
Human noroviruses (HuNoVs) are considered the main cause of diarrheal episodes and
foodborne gastroenteritis globally (11–13), with an estimated 500 M infections
annually and 200,000 associated fatalities (13). Mortality rates are especially high in
children under the age of 5 living in low-income countries, although other cohorts of
vulnerable patients include elderly and immunocompromised populations (11, 14).
HuNoV infections have also been linked to effects on an increasing number of other
severe disorders such as exacerbation of inﬂammatory bowel disease, ulcerative colitis,
and life-threatening chronic diarrhea (15, 16). Despite the signiﬁcant impact on global
health and the elevated economic losses associated with HuNoVs (11), there are no
licensed vaccines or antiviral drugs available for the treatment of disease and control
of outbreaks.
Since 2002, a sharp increase in the global incidence of norovirus outbreaks that is
associated with the emergence of genogroup II.4 (GII.4) pandemic strains has been
reported (17, 18). Evidence suggests that emerging HuNoV GII.4 pandemic strains
transmit from person to person more efﬁciently than the previously dominant geno-
group I strains (19, 20). Recent studies have demonstrated that the viral RNA-
dependent RNA polymerases from pandemic HuNoV GII.4 strains display reduced
replication ﬁdelity and increased intrahost diversity in their resulting viral populations
in comparison to nonpandemic strains (21). A newly emerging HuNoV GII.17 isolate,
ﬁrst identiﬁed in China, seems to be outcompeting the HuNoV GII.4 in some parts of
Asia, resulting in increased outbreaks since the winter season of 2014 to 2015 (22).
Recent studies suggest that this novel variant may be spreading globally, which could
lead to the replacement of the pandemic genotype GII.4 by GII.17 (22–26). Fitting with
the hypothesis that ﬁdelity is linked to rapid emergence of norovirus isolates, the GII.17
isolate displays evolutionary rates at least 1 order of magnitude higher than those seen
with GII.4 (25). Despite this evidence, a possible relationship between the reported
reduced ﬁdelity (and greater genetic diversity) in pandemic HuNoV GII.4 and the
emerging GII.17 isolates and increased transmissibility has yet to be examined.
Here, we have assessed the inﬂuence of polymerase ﬁdelity and genetic diversity on
norovirus infectivity and transmission in vivo using a persistent strain of murine
norovirus (MNV) as a model. MNV provides a robust surrogate system for studying
HuNoV ﬁdelity due to its high replication rates in cultured cells and to the availability
of efﬁcient reverse genetics systems and small-animal models (10, 27, 28). Here we have
identiﬁed a high-ﬁdelity MNV polymerase mutant (I391L) which shows delayed repli-
cation kinetics during the establishment of a persistent infection in vivo. Despite being
able to successfully establish an infection and persist, the high-ﬁdelity I391L mutant
showed reduced mouse-to-mouse transmission compared to wild-type (WT) virus.
Signiﬁcantly, the transmission of a mutant with in vivo replication kinetics similar to
those of the I391L mutant, but with WT-like polymerase ﬁdelity (S313T), was unaffected,
suggesting that the reduced transmission of I391L was linked to ﬁdelity. These results
support the role of genetic diversity as a signiﬁcant trait inﬂuencing norovirus infec-
tivity and transmission in vivo and provide new insight into the potential role of
polymerase ﬁdelity in the emergence of norovirus strains.
RESULTS AND DISCUSSION
Generation of MNV polymerase ﬁdelity mutant candidates. With the aim of iden-
tifying possible MNV polymerase (NS7) ﬁdelity mutants, we carried out site-directed
mutagenesis of residues previously identiﬁed as ﬁdelity determinants in the ortholo-
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gous positions of other viral RNA-dependent RNA polymerases. Given the substantial
amount of data available on picornavirus polymerases and their relatively close genetic
relationship with caliciviruses, we designed mutations in the MNV polymerase based on
previous studies with poliovirus (PV), foot-and-mouth disease virus (FMDV), and cox-
sackievirus (CV) (3–5, 29–32). To date, the most paradigmatic example of viral attenu-
ation as a result of increased ﬁdelity is the PV polymerase (3Dpol) G64S mutation, which
resulted in a loss of pathogenicity with restricted virus tissue tropism in a lethal mouse
model of PV infection (3, 4). While the norovirus polymerases do not share a great
degree of structural homology with the PV 3Dpol in the domain surrounding the G64S
position, MNV NS7 residue R77 (R74 in HuNoV NS7) lies within this domain and similarly
establishes multiple hydrogen bond interactions with residues in the active site (30, 33,
34). The G64S change in PV 3Dpol is thought to alter ﬁdelity by changing the hydrogen
bond network, indirectly leading to subtle conformational changes of catalytic site
residues (8, 30). Therefore, we examined the impact of substitutions at amino acid R77
on virus replication by reverse genetics (Table 1). All the mutations studied were lethal
in the context of the MNV infectious clone, suggesting that this position is critical for
TABLE 1 Summary of the design and cell culture characterization of NS7 mutants
Mutant in orthologous viral
polymerasea
Fidelity in orthologous
virus polymeraseb
MNV NS7
mutantc
MNV
straind
Viable in
MNVe
Replication in cell
culturef Replication in vivog
PV G64S High V65S (1) No
L70S (1) No
P72S (1, 3) Yes Modest increase Modest increase
E75S (1, 3) Yes Modest increase WT
R77A (1) No
R77K (1) No
R77N (1) No
R77S (1) No
G78S (1) No
FMDV P169S/CV S164P High/low K174R (3) Yes WT WT
K174S (3) Yes Signiﬁcantly decreased Signiﬁcantly decreased
P175S (3) No
CV S298T Low S313T (3) Yes Modest decrease Signiﬁcantly decreased
CV A372V Low I391D (3) No
I391L (3) Yes WT Signiﬁcantly decreased
I391R (3) No
I391V (3) Yes WT WT
Isolated by passage in ribavirin T35I (3) Yes WT Modest decrease (viral RNA)
Isolated by passage in ribavirin V330I (3) Yes WT WT
Designed based on MNV V330I V330A (3) No
V330S (3) No
aSubstitutions generated in this study were based on ﬁdelity changes found in other viruses (4, 5, 29, 31, 32): G64S in PV; P169S in FMDV; and S164P, S298T, and
A372V in CV.
bEffect on virus polymerase ﬁdelity caused by substitutions shown in the ﬁrst column.
cMNV NS7 polymerase mutants generated based on the ﬁdelity of the residues shown in the ﬁrst column. Mutants V330I and T35I were constructed after isolation of
these mutations in MNV populations treated with increasing concentrations of ribavirin (see Fig. S1 in the supplemental material). Other variants of position 330
(V330A or -S) were also prepared based on the isolation of V330I during ribavirin treatment. These mutants were not viable.
dMNV strain. NS7 mutations were introduced in plasmids containing full MNV-1 or MNV-3 genome sequences. Hence, “(1)” denotes MNV-1, “(3)” denotes MNV-3, and
“(1, 3)” denotes those mutations tested in both strains. For the experiments represented in the ﬁgures, only MNV-3 variants were used.
eThe viability of NS7 mutants was assessed by reverse genetics after recovery in BHK-21 (or BHK-21-derived BSR-T7) cells followed by 3 serial passages in RAW264.7
cells as described in reference 27.
fPhenotype in cell culture. “Modest increase or decrease” (in virus replication) indicates statistically signiﬁcant changes in virus titers of 1 log10 (two-way analysis of
variance [ANOVA] test) at any given time point during replication kinetics. “Signiﬁcantly decreased” in virus replication (K174S) refers to statistically signiﬁcant
changes in virus titers of ~2 log10 at an early replication time point. In this column, “P72S” and “E75S” refer to the corresponding NS7 mutants in the MNV-3 genome
context.
gPhenotype in vivo. “Modest increase” (in virus replication) in vivo indicates a highly signiﬁcant change in the titer of virus shed in feces (1 log10; P  0.001; two-
way ANOVA). “Signiﬁcantly decreased” indicates highly signiﬁcant changes in levels of both viral RNA and infectious virus shed in feces (P  0.001; ANOVA test).
“Modest decrease (viral RNA)” indicates signiﬁcantly lower RNA levels but not virus titers shed in mouse feces. In this column, “P72S” and “E75S” refer to the
corresponding NS7 mutants in the MNV-3 genome context.
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polymerase function (Table 1). In order to identify tolerated MNV variants in this region
of NS7, we mutated several neighboring amino acids of R77 that were not predicted to
establish as many direct hydrogen bonds with amino acids involved in the active site
and that would be predicted to result in more-subtle rearrangements of motif A. A
series of positions, including V65, L70, P72, E75, and G78, were identiﬁed as possible
tolerant sites within NS7 (Table 1). We also identiﬁed homologous positions in MNV NS7
based on other ﬁdelity variants isolated in related picornaviruses, such as CV and FMDV,
namely, K174, P175, S313, and I391 (Table 1). We successfully recovered mutants
encoding NS7 substitutions P72S, E75S, K174R, K174S, S313T, I391L, and I391V, whereas
the remaining mutants were nonviable (Table 1). The recovery of K174S and S313T
yielded lower virus titers than the MNV WT, suggesting reduced replication ﬁtness
associated with these polymerase changes (Table 1). The stability of the viable mutants
was conﬁrmed by sequencing virus populations obtained after 4 serial passages in cell
culture, with no additional changes identiﬁed within the NS7-coding region for any
mutant (data not shown).
Since the propagation of different RNA viruses in cell culture in the presence of
ribavirin generally leads to the selection of ﬁdelity mutants (e.g., PV G64S, FMDV P169S,
and CV A372V, among others) (29, 31, 32), we similarly investigated whether the
passage of MNV in the presence of ribavirin also selected for changes in NS7 conferring
higher polymerase ﬁdelity. We identiﬁed substitutions T35I and V330I in NS7, which
emerged in two lineages of MNV that had been repeatedly passaged in the presence
of ribavirin (see Fig. S1 in the supplemental material). No substitutions were found in
the NS7 RNA polymerase of MNV passaged in parallel in the absence of the drug. These
mutations were introduced in the MNV infectious cDNA clone, and viable mutants were
recovered (Table 1).
Substitution I391L results in increased polymerase ﬁdelity. As an indirect
approach to identify any ﬁdelity alterations in the viable MNV mutants, we tested the
sensitivity of the viable mutants to the following three different nucleoside analogues
with mutagenic activity against a variety of RNA viruses, including MNV: favipiravir,
5-ﬂuoruracil, and ribavirin (3, 5, 10, 35). High-ﬁdelity mutants are typically less sensitive
to mutagenic treatment, while mutator (lower ﬁdelity) polymerase variants are typically
more sensitive (5, 29, 32). The I391L mutant had reduced sensitivity to all three
mutagenic compounds, while the S313T mutant was more sensitive to 5-ﬂuorouracil
and favipiravir (Fig. 1). I391V sensitivity varied depending on the mutagenic compound,
and the I391V mutant was more sensitive to 5-ﬂuorouracil and favipiravir and less
sensitive to ribavirin (see Fig. S2 in the supplemental material). The remaining mutant
viruses showed no signiﬁcant differences in their sensitivities to any of these mutagenic
compounds compared to the WT (see Fig. S3).
Given this pattern of sensitivity to different mutagenic nucleosides, substitutions
I391L, I391V, and S313T were further examined for any impact on replication ﬁdelity.
Several studies have demonstrated that alterations in polymerase ﬁdelity typically lead
to changes in the genetic diversity of the resulting virus population (4, 5). With this in
mind, we measured the genetic diversity in MNV NS7 mutant populations after their
serial passage in cell culture in the absence of any mutagenic treatment. We found that
the genetic diversity in the I391L NS7 mutant virus population was ~3-fold lower than
in the WT NS7 population, suggesting that the I391L substitution results in a higher-
ﬁdelity NS7 (Fig. 1D; see also Table S1 in the supplemental material). The NS7 mutants
S313T and I391V did not show any signiﬁcant difference in their mutation frequencies
compared to the WT, suggesting that their increased sensitivity to mutagens was not
related to any impact on polymerase ﬁdelity (Fig. 1D; see also Fig. S2D and Table S1).
Hence, the S313T and I391V mutants display WT-like ﬁdelity phenotypes.
The high-ﬁdelity I391L NS7 mutant shows delayed replication in vivo but
not in cell culture.We investigated whether the increase in ﬁdelity conferred by I391L
resulted in any phenotypic alteration of norovirus replication in vivo, as previously
documented for other viruses (4, 9). Prior to this, a more detailed characterization of the
replication kinetics of the I391L mutant and the remaining NS7 mutants was performed
Arias et al.
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in cell culture. The I391L mutant showed no signiﬁcant difference from WT MNV in
terms of the virus yields obtained following viral recovery by reverse genetics from a
full-length cDNA construct (Fig. 2A). Similarly, no replication defect was observed at
either a low multiplicity of infection (MOI) (0.01 50% tissue culture infective dose
[TCID50]/cell; Fig. 2B) or a high MOI (5 to 10 TCID50/cell; Fig. 2C and D) for immortalized
macrophage cells. However, I391L showed signiﬁcantly delayed kinetics of replication
in vivo as reﬂected in decreased viral RNA levels and lower titers of infectious virus
secreted in the feces of the mice (Fig. 3A and B). This observation suggests that the
higher replication ﬁdelity of I391L results in reduced ﬁtness during the establishment
of a persistent infection in vivo. The early defect in I391L replication was recovered by
day 3 postinfection (Fig. 3A and B) and then remained comparable to the WT level for
the duration of the experiment (28 days; data not shown). Animals infected with a
10-fold-higher viral titer also showed delayed replication kinetics for I391L, although
viral loads similar to the WT levels were again observed by day 2 (Fig. 3C). The observed
lower virus titers and RNA levels in feces of mice infected with I391L were associated
FIG 1 Substitution I391L in the MNV NS7 RNA polymerase leads to restricted genetic diversity in
viral populations. (A to C) Sensitivity of the WT strain and mutants I391L and S313T to different
mutagenic compounds: 5-fluorouracil (A), favipiravir (B), and ribavirin (C). Sensitivity to each muta-
gen is expressed as the change in virus titer relative to the value for infections in the absence of
mutagens. Each value is the average of results of three independent biological replicates (n 3), with
the error bars representing standard errors of the means (SEM). An apparent absence of SEM bars
indicates that the bar is smaller than the respective symbol for these values. Sensitivity values for
each MNV NS7 mutant were compared with WT values. Hence, those mutants with titer change
curves above the WT curve were less sensitive to drug treatment, whereas those with curves below
the WT curve showed greater sensitivity. Statistical analysis of relative levels of sensitivity in each
NS7 mutant compared to the WT was performed by two-way analysis of variance (ANOVA) (*, P <
0.05; **, P< 0.01; ***, P< 0.001). (D) Mutation frequency analysis of MNV populations obtained after
8 serial passages in RAW264.7 cells in the absence of mutagenic treatment. Viral RNA was extracted
and amplified by RT followed by PCR as explained in Materials and Methods. Amplified cDNA
molecules were ligated to PCR Blunt vector, and positive colonies containing MNV insertions were
sequenced. Statistical significance in the genetic diversity of different mutant viruses (S313T and
I391L) with respect to that of the WT was determined by a Mann-Whitney test, which was used to
compare the ranked scores of the numbers of mutations found in individual clones grouped by
population, as further explained in Materials and Methods (ns, not significant; **, P< 0.05). Repeated
mutations were taken into consideration only once for the analysis, as previously described (10).
These mutation frequencies correspond to the identification of 34, 23, and 10 unique mutations
during the sequence analysis of 127,870, 71,844, and 117,540 nucleotides (nt) in molecular clones
from WT, S313T, and I391L populations, respectively. The total numbers of clones analyzed (n) in this
study were 60, 34, and 56 for the WT, S313T, and I391L populations, respectively.
Increased Fidelity Reduces Virus Transmission
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with a trend toward lower viral RNA levels in different tissues harvested at 48 h
postinoculation, although the differences observed did not reach statistical signiﬁcance
(Fig. 3D).Taking the data together, the reduced replication kinetics of the MNV I391L
NS7 mutant were apparent only in vivo and not during replication in cell culture. This
is in line with observations of other reported ﬁdelity mutants (4, 32).
Of the remaining NS7 mutants, S313T and K174S also displayed decreases in
replication in vivo to levels similar to those seen with I391L (Fig. 3A and B; see also
Fig. S4 in the supplemental material). However, in contrast to I391L, both S313T and
K174S also displayed small but signiﬁcant replication defects in cell culture. Both the
S313T and K174S mutants yielded reduced virus titers in virus recoveries by reverse
genetics (Fig. 2A; see also Fig. S4A) that were typical of viruses with a replication defect.
K174S also showed signiﬁcantly delayed kinetics during infection in RAW264.7 cells (see
Fig. S4B). In contrast, the S313T mutant displayed minimally but reproducibly lower
virus titers at 16 h postinfection during kinetics assays performed with both high and
low MOI’s (Fig. 2B to D). The mutants I391V and T35I exhibited modest replication
defects in vivo, although to a lesser extent than I391L (see Fig. S4 and S5). Surprisingly,
signiﬁcantly higher numbers of genome copies were secreted in mice infected with the
P72S mutant, with slightly increased replication also being observed in cell cultures (see
Fig. S6), suggesting that this substitution confers a replication advantage to MNV. Given
that P72S did not differ in its sensitivities to mutagenic nucleosides, we hypothesized
that the observed phenotype was not due to any impact on ﬁdelity and it was therefore
not characterized in more detail.
We subsequently investigated whether the reduced replication of I391L in mice
could be rescued by a chemical expansion of the quasispecies diversity by favipiravir
treatment. We have previously demonstrated that favipiravir elicits antiviral mutagenic
activity associated with increased genetic diversity of the viral quasispecies in vivo (10).
FIG 2 The MNV NS7 RNA polymerase mutant I391L shows WT-like replication kinetics during
infection in cell culture. (A) Virus yield after reverse genetics recovery of full-length cDNA constructs
containing either wild-type (WT) MNV or the polymerase mutants S313T and I391L. The values shown
are the averages of results of at least three independent virus titer determinations for up to 4
independent cDNA transfections. Error bars represent SEM, with the statistical significance deter-
mined by one-way ANOVA (ns, not significant; ***, P < 0.001). (B to D) Replication kinetics of WT and
mutant MNVs in RAW264.7 cells infected at the following different MOI’s: 0.01 TCID50/cell (B), 5
TCID50/cell (C), and 10 TCID50/cell (D). The values represent the averages of results of three inde-
pendent biological replicates (n  3), with the error bars representing SEM. Data were analyzed by
two-way ANOVA (*, P < 0.05). The dashed line in panels A to C represents the limit of detection.
Arias et al.
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Treatment of mice with favipiravir resulted in decreased virus titers shed by both WT
MNV and I391L MNV-infected animals (Fig. 4), suggesting that the dose of favipiravir
used elicits antiviral activity against both viruses. Despite this, I391L displayed greater
tolerance than the WT to favipiravir during infection in vivo, in agreement with
observations in cell culture (Fig. 1B).
The high-ﬁdelity MNV NS7 I391L mutant is transmitted less efﬁciently than
the WT and the S313T mutant in vivo. Several studies have found that viral genetic
diversity contributes to organ and tissue tropism expansion during viral infections by
facilitating avoidance of or escape from different physiological barriers (3, 4, 36).
However, there is limited information on whether genetic diversity contributes to virus
transmission between susceptible hosts. Recent studies suggest that reduced polymer-
ase replication ﬁdelity may be a signiﬁcant determinant linked to the pandemic
expansion of recent HuNoV GII.4 isolates (21) and that person-to-person transmission is
more efﬁcient for GII.4 pandemic strains than for nonpandemic isolates (19, 20). To
determine whether the high-ﬁdelity I391L NS7 mutant had altered transmission in vivo,
we established an MNV transmission model whereby one mouse per cage was orally
inoculated and transmission to ﬁve sentinel littermates was monitored by quantiﬁca-
FIG 3 MNV NS7 RNA polymerase mutant I391L shows delayed replication kinetics in mice. (A and B)
Virus titers (A) and viral RNA levels (B) shed in the feces of animals inoculated with 3  102 TCID50
MNV (n  5). Mice were inoculated with recombinant viruses generated following recovery of MNV
NS7 variants in BHK-21 cells by reverse genetics followed by 4 serial infections in RAW264.7 cells, as
previously described (39). The presence of the desired mutations in the viral genome was confirmed
by sequencing. Data were analyzed by two-way ANOVA (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
gRNA eq, genomic RNA equivalents. (C) Animals were infected as described for panel A, but the mice
were inoculated with a dose of 3  103 TCID50 MNV per mouse (n  5). Data represent results from
a two-way ANOVA test (***, P< 0.001). (D) Viral RNA levels detected in various tissues collected from
mice inoculated with 3  102 TCID50 of WT MNV or the NS7 polymerase mutants at 48 h postinfec-
tion. MLN, mesenteric lymph node (two-way ANOVA test results were nonsignificant). In all panels,
the dashed line represents the detection limit. The apparent absence of SEM bars for some values in
panels B and C indicates that the bar is smaller than the respective symbol.
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tion of viral RNA in the feces. Since a defect in transmission could be attributed to
delayed replication in I391L-infected mice, we also included the S313T mutant as it
exhibits WT-like polymerase ﬁdelity (Fig. 1D) but slower replication in vivo, to an extent
similar to that seen with the I391L mutant (Fig. 3A and B). We found that transmission
rates for the I391L mutant were signiﬁcantly lower than those found for the WT and
S313T (Fig. 5), suggesting that genetic diversity is linked to efﬁcient virus transmission
between hosts. Reduced transmission in the I391L-infected group was associated with
lower viral RNA levels shed in the feces of sentinel animals (see Fig. S7 in the
supplemental material). Hence, changes in polymerase ﬁdelity may impact the rate of
transmission of noroviruses within a susceptible population of naive hosts, providing
additional support to recent studies indicating that the pandemic HuNoV GII.4 isolates
possess polymerases with lower ﬁdelity (21, 28).
In this study, we demonstrated that a high-ﬁdelity norovirus mutant has reduced
replication in vivo accompanied by reduced rates of transmission between hosts. This
FIG 4 MNV NS7 RNA polymerase mutant I391L is less sensitive to favipiravir treatment in vivo. Six
animals were infected with 3  102 TCID50 MNV (n  6). After 7 days, persistently infected mice were
subjected to favipiravir treatment twice a day over a period of 4 days. Mouse feces samples were
collected, and the titers (TCID50 per gram) were determined as previously described (10). The virus
titer values represented are relative to the average virus titer at the day 0 time point, collected
immediately before the beginning of treatment. Absolute virus titer values at day 0 were 5.80 and
5.51 log10 TCID50/g stool for the WT and the I391L mutant, respectively. Error bars represent SEM
from a two-way ANOVA test (ns, not significant; *, P < 0.05; **, P < 0.01).
FIG 5 MNV NS7 RNA polymerase mutant I391L shows delayed transmission in susceptible hosts. Virus transmission from
infected to uninfected mice was determined as detailed in Materials and Methods. In brief, five naive mice in each cage
were housed with one mouse inoculated by oral gavage with 3  102 TCID50 MNV-3. Every mutant was tested in 4
independent cages (n  20). MNV transmission was determined by qPCR detection of MNV in the feces of naive mice
along a series of time points. (A and B) Graphs showing the percentages of noninfected animals along a series of time
points (the log rank test was used for statistical analysis). (A) WT and S313T showed no significant (ns) difference in their
transmission kinetics between mice. (B) The WT strain was transmitted significantly faster than the I391L mutant (**; P <
0.01). S313T also showed significantly increased transmission compared to I391L (not shown in the figure; P < 0.05).
Animals directly infected by oral-gavage inoculation are not represented. (C) Viral RNA levels found in the feces of
noninoculated animals after 4 days in contact with infected mice (n  20). The dashed line represents the limit of
detection, and the numbers above the groups represent the numbers of animals shedding viral RNA at levels below the
detection limit. Animals directly infected by oral-gavage inoculation are not represented. Data represent results of a
two-way ANOVA test (**, 0.001 < P < 0.01).
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report builds on our previous investigations demonstrating that norovirus replication
ﬁdelity and intrahost genetic diversity inﬂuence viral pathogenesis (10). Together, these
results are highly signiﬁcant in light of understanding the inﬂuence of replication
ﬁdelity on factors that affect the emergence of new norovirus variants with pandemic
potential. Given the recent development of potential cell culture propagation methods
for HuNoVs (37, 38), the identiﬁcation of ﬁdelity determinants in NS7 could also
contribute to the design of genetically stable attenuated vaccines, as has been pro-
posed for other viruses (8).
MATERIALS AND METHODS
Ethics. Studies with mice were performed in the Department of Pathology Biostatistics Unit (BSU) (PCD
80/2802) after ethical review by the University of Cambridge Review Panel and subsequent approval by
the United Kingdom Home Ofﬁce (PPL70/7689). All animal procedures and care conformed strictly to the
United Kingdom Home Ofﬁce Guidelines under the Animals (Scientiﬁc Procedures) Act 1986.
Animal infections and antiviral treatment. Male C57BL/6 mice (4 to 5 weeks old) were orally
infected with known amounts of MNV-3 as previously described (10) and as stated in the text. Fecal
samples were collected at different time points, and the presence of infectious particles and viral RNA
was determined as described in reference 10. For the determination of viral RNA levels in tissues, animals
were euthanized at 48 h postinfection and the cecum, colon, and mesenteric lymph node harvested.
Mice infected with MNV-3 were treated with favipiravir following protocols previously described in
reference 10. Brieﬂy, 1 week after inoculation, persistently infected animals were treated twice a day by
oral gavage with favipiravir (600 mg/kg of animal body weight/day) for 4 days. Fecal samples were
collected at different times during the course of treatment and virus titers and RNA levels quantiﬁed.
Viral transmission experiments. To determine MNV transmission in vivo, we scored the proportion
of infected mice within the population of noninoculated animals in contact with mice infected by
oral-gavage inoculation. One mouse was inoculated per cage and was housed with ﬁve contact
uninfected sentinel mice. We determined the presence of MNV RNA in the feces of naive mice at different
time points postinfection (days 1, 2, 3, 4, and 6).
Cells, infections, and reverse genetics recovery of viruses. Procedures for the cultivation of cells
and MNV infections have been previously described (10). RAW264.7 murine leukemia macrophage cells
were used for the propagation and titration (TCID50 assay) of the MNV-1 and MNV-3 mutants used in this
study. All the different cell lines were cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) with 10%
FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete DMEM) and were maintained at 37°C
with 5% CO2.
The wild-type strain and NS7 mutants MNV-1 and MNV-3 used in this study were obtained after
reverse genetics recovery of infectious virus as previously described (10, 27). Brieﬂy, BHK-21 cells were
transfected with plasmids containing a T7 promoter followed by full-length genomic MNV cDNA
encoding different NS7 mutants. Then, transfected cells were infected with helper fowlpox virus
expressing recombinant T7 polymerase (FPV-T7) as previously described in reference 27. The resulting
population was titrated and used as a passage 0 stock. All the experiments carried out in this study
involved NS7 mutants in the context of an MNV-3 genome, with the exception of a limited number of
NS7 mutant virus recoveries described in Table 1 that were generated in the context of an MNV-1
genome.
Cell culture infections in the presence of mutagenic compounds. Experiments performed to
determine levels of sensitivity to different mutagenic compounds were carried out using RAW264.7 cells.
A total of 4  105 cells per well were seeded on 24-well plates, incubated for 3 h at 37°C and 5% CO2
to allow attachment to the plate, and then infected with different MNV mutants at an MOI of 0.01
TCID50/cell. Cells were incubated at 37°C and 5% CO2 for 1 h; the supernatants were then removed and
cells washed once with complete DMEM, before addition of 1 ml of complete DMEM containing
mutagenic compounds at the indicated concentrations. Infections were harvested at 42 h and virus
progeny released through 2 consecutive cycles of freeze-thawing.
Viral RNA extraction, reverse transcription-PCR (RT-PCR) ampliﬁcation, quantitative PCR
(qPCR), and mutation frequency analysis of virus populations. Viral RNA was extracted from 100 l
of viral samples (either supernatant from lysed infected cultures or phosphate-buffered-saline [PBS]-
resuspended feces from animals) using a GenElute RNA miniprep puriﬁcation system following protocols
provided by the manufacturer. Viral RNA was quantiﬁed using a two-step qPCR approach following
protocols described previously (27).
For the calculation of mutation frequency in any virus population, we followed protocols previously
described (10). We analyzed the mutation frequency of mutant and WT populations obtained after eight
passages in RAW264.7 cells to allow sufﬁcient rounds of replication and accumulation of mutations to
facilitate the quantitative analysis. Brieﬂy, 4 l of puriﬁed RNA was subjected to reverse transcription in
a 20-l ﬁnal volume using SuperScript III (Roche) as indicated by the manufacturer. cDNA (3 l) was then
PCR ampliﬁed using high-ﬁdelity Hot Start KOD DNA polymerase (Toyobo) and primers spanning MNV-3
genomic positions 951 to 3395. Positive PCR band products were excised from an agarose gel and
puriﬁed with EconoSpin columns (Epoch) and then directly ligated to plasmid PCR Blunt using a Zero
Blunt PCR cloning kit (Life Technologies). Positive Escherichia coli colonies were identiﬁed by PCR
screening using primers ﬂanking the vector-cloning site and GoTaq polymerase (Promega). The resultant
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PCR products corresponding to individual MNV cDNA clones were sequenced, and the mutation
frequency in each population was calculated.
Statistical analysis. Statistical signiﬁcance was examined using GraphPad Prism as described in the
ﬁgure legends. For statistical analysis of mutation frequencies, a Mann-Whitney test was used that
compares the ranked scores of the numbers of mutations found in individual clones grouped by
population (Mann-Whitney test; 0.01  P  0.05, **), as previously described (5).
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